Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis on Drug Targeting to Cancer Cells through Nanoparticles

Awasthi, R; Singh, AK; Mishra, G; Maurya, A; Dhiman, N; Kharkwal, H; Sharma, B; Jha, NK; Dureja, H; Dua, K; de Jesus Andreoli Pinto, T; Kulkarni, GT

Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis on Drug Targeting to Cancer Cells through Nanoparticles

Awasthi, R Singh, AK Mishra, G Maurya, A Dhiman, N Kharkwal, H Sharma, B Jha, NK Dureja, H Dua, K

de Jesus Andreoli Pinto, T Kulkarni, GT

Permalink

Publisher:: Bentham Science Publishers
Publication Type:: Journal Article
Citation:: Letters in Drug Design and Discovery, 2023, 20, (5), pp. 499-516
Issue Date:: 2023-01-01

Closed Access

	Filename	Description	Size
	21848885_12586469560005671.pdf		6.66 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Awasthi, R
dc.contributor.author	Singh, AK
dc.contributor.author	Mishra, G
dc.contributor.author	Maurya, A
dc.contributor.author	Dhiman, N
dc.contributor.author	Kharkwal, H
dc.contributor.author	Sharma, B
dc.contributor.author	Jha, NK
dc.contributor.author	Dureja, H
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	de Jesus Andreoli Pinto, T
dc.contributor.author	Kulkarni, GT
dc.date.accessioned	2024-01-10T23:19:13Z
dc.date.available	2024-01-10T23:19:13Z
dc.date.issued	2023-01-01
dc.identifier.citation	Letters in Drug Design and Discovery, 2023, 20, (5), pp. 499-516
dc.identifier.issn	1570-1808
dc.identifier.issn	1875-628X
dc.identifier.uri	http://hdl.handle.net/10453/174244
dc.description.abstract	Lung cancer is a leading cause of cancer-related deaths globally. The availability of successful anticancer agents in the market is limited, and the development process of a new drug molecule is slow and difficult. The currently available commercial formulations are not sufficient to produce the desired therapeutic response within a specific time limit. Therefore, there is an urgent need to develop novel nanocarrier-based therapies to defeat the restrictions of existing therapeutics. Nanoparticles have been investigated as novel formulations but are often inefficient in practical applications. However, several unanswered questions and challenges exist in their clinical development; thus, a better understanding of their influence on cancer biology, stability, and toxicity needs to be gained. This review discusses different types of lung cancers as well as diagnostic approaches to lung cancer. The review also explores the drug targeting mechanisms to cancer cells through nanoparticles and multi-drug resistance-associated challenges in lung cancer therapy. Various nanocarrier systems that are safe and effective for drug delivery in the treatment of lung cancer have been discussed. This communication will be of high relevance to the biological, formulation, and translational scientists working in the field of cancer biology and drug delivery.
dc.language	en
dc.publisher	Bentham Science Publishers
dc.relation.ispartof	Letters in Drug Design and Discovery
dc.relation.isbasedon	10.2174/1570180819666220510133408
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1101 Medical Biochemistry and Metabolomics, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	3404 Medicinal and biomolecular chemistry
dc.title	Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis on Drug Targeting to Cancer Cells through Nanoparticles
dc.type	Journal Article
utslib.citation.volume	20
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1101 Medical Biochemistry and Metabolomics
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-01-10T23:19:10Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	20
utslib.citation.issue	5

Abstract:

Lung cancer is a leading cause of cancer-related deaths globally. The availability of successful anticancer agents in the market is limited, and the development process of a new drug molecule is slow and difficult. The currently available commercial formulations are not sufficient to produce the desired therapeutic response within a specific time limit. Therefore, there is an urgent need to develop novel nanocarrier-based therapies to defeat the restrictions of existing therapeutics. Nanoparticles have been investigated as novel formulations but are often inefficient in practical applications. However, several unanswered questions and challenges exist in their clinical development; thus, a better understanding of their influence on cancer biology, stability, and toxicity needs to be gained. This review discusses different types of lung cancers as well as diagnostic approaches to lung cancer. The review also explores the drug targeting mechanisms to cancer cells through nanoparticles and multi-drug resistance-associated challenges in lung cancer therapy. Various nanocarrier systems that are safe and effective for drug delivery in the treatment of lung cancer have been discussed. This communication will be of high relevance to the biological, formulation, and translational scientists working in the field of cancer biology and drug delivery.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174244